Sara AS, Eslam MS, Mohamed Raslan and Nagwa A Sabri*
Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
*Corresponding Author: Nagwa A Sabri, Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Received: September 05, 2020; Published: October 08, 2020
Background: Corona virus 2019 is considered one of the most widely spreaded pandemics that significantly affected healthcare and economic development worldwide and the probability of development of a second wave of this pandemic is high. Several protocols used fluoroquinolones antibiotics, including moxifloxacin, which are one of the promising adjuvant therapy in management of Corona virus 2019 disease.
Aim: Development of a novel, sensitive and validated LC/MS/MS bio-analytical method for the determination of moxifloxacin in biological fluids and its applications in pharmacokinetics, bioequivalence studies and monitoring drug-plasma levels to assure its effectiveness in management of infections.
Methods: Protein precipitation technique was used for moxifloxacin extraction from human plasma using ciprofloxacin as an internal standard, where, human plasma samples were analyzed using the following chromatographic conditions: eluting solvent consisting of 0.5% formic acid and acetonitrile 45: 55 v/v, pumped at flow rate 0.55 ml/min, ionization mode was set on ESI positive mode, and mass to charge ratio was m/z 402à261, 332à231 for moxifloxacin and ciprofloxacin respectively. Application on bioequivalence study of moxifloxacin generic versus reference product was assessed in 24 healthy subjects, where, AUC0-t, AUC0-inf, Cmax, and Tmax. were reported.
Results: The mean recovery of moxifloxacin from human plasma was 80.108%, the lower limit of quantitation was 0.05 ug/ml and the Correlation coefficient (r2) was equal to 0.9994. Statistical analysis for the pharmacokinetic parameters using analysis of variance (ANOVA) showed a non- significant difference between generic and reference drug products.
Conclusion: The developed LC/MS/MS method proved to be simple, sensitive, selective and valid for the detection of moxifloxacin in human plasma which can be applicable in pharmacokinetic studies, therapeutic drug monitoring in different patient care settings.
Keywords: ANOVA; Corona Virus; COVID-19
Citation: Nagwa A Sabri., et al. “Moxifloxacin as an Adjuvant Therapy in Management of COVID-19. What is Behind its Accurate Determination in Human Plasma and Pharmacokinetics Applications?". Acta Scientific Pharmaceutical Sciences 4.11 (2020): 30-37.
Copyright: © 2020 Nagwa A Sabri., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.